Regenerative medicine company TEI Biosciences said that it has been awarded a supply contract by group purchasing organization Novation for its biologic mesh products.
The three-year contract, which starts April 1, will make TEI products such as SurgiMend available to more than 100,000 Novation members, including VHA, UHC, the Children’s Hospital Association and Provista. The products, which are derived from bovine collagen, are used in plastic surgery, reconstructive surgery and hernia repair.
“The Novation contract award is a recognition of both the strong clinical efficacy and powerful economic value our SurgiMend products can provide the Novation member hospitals,” said TEI CEO Yiannis Monovoukas, in a statement. “This agreement strengthens TEI’s ability to work with the thousands of hospitals served by Novation, and we are delighted that more patients than ever may now benefit from the regenerative and life-changing effects of our SurgiMend platform technology.”
Last fall, Novation inked a sole-source deal with Edwards Lifesciences for replacement heart valves.